Fulcrum (FULC) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Globe and Mail, The
Chief Financial Officer — Alan Musso Chief Medical Officer — Iain Fraser Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS PIONEER Phase Ib Results -- Pociredir demonstrated an increase in average fetal hemoglobin (HbF) from 7.1% to 19.3% after 12 weeks of once-daily 20 mg dosing, with observed improvements in hemolysis and anemia markers. Vaso-Occlusive Crisis (VOC) Data -- Seven out of twelve patients experienced no VOCs during the 12-week treatment period in the PIONEER trial. Safety -- Pociredir remained generally well tolerated, with no treatment-related serious adverse events reported to date. Long-Term Dosing Study -- An open-label extension trial for PIONEER participants was initiated, with the first patient enrolled and a focus on long-term safety, durability of response, and response after reinitiation. Cash Position -- Cash, cash equivalents, and marketable securities totaled $333.3 million at quarter-end, down from $352.3 million as of D
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics GAAP EPS of -$0.25 beats by $0.05 [Seeking Alpha]Seeking Alpha
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026GlobeNewswire
FULC
Earnings
- 4/27/26 - Beat
FULC
Analyst Actions
- 2/24/26 - Leerink Partners
FULC
Sec Filings
- 4/27/26 - Form 10-Q
- 4/27/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- FULC's page on the SEC website